Back

Sex-specific effects of apixaban versus aspirin in subclinical atrial fibrillation: insights from the ARTESiA trial

12 April 2026 (10:26 - 10:37)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation and stroke Stroke in Atrial Fibrillation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Julia Wiebke Erath

Goethe University Hospital, Frankfurt (Germany)

3 More presentations in this session

Presentation thumbnail
Female sex-related stroke risk in atrial fibrillation: a thing from the past?
Doctor K. Teppo (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Ceasing anticoagulation after ablation associated tamponade does not increase stroke risk
Doctor R. Muthalaly (London, GB)
Abstract Slides Video
Presentation thumbnail
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation: a reconstructed patient level meta-analysis
Mr L. Barbosa (Belo Horizonte, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation and stroke
Video

The Event

Event poster

EHRA 2026

12 April 2026 10:26 CET
You may be interested in
thumbnail
Congress Presentation
Predictors and Outcomes of Atrial Fibrillation Progression in Patients with Device-Detected Subclinical AF: Insights from the ARTESiA Trial
thumbnail
Congress Presentation
Comorbidity patterns and health-related outcomes in older adults with atrial fibrillation: nationwide population-based findings from swedish national patient register
thumbnail
Congress Presentation
STEEER-AF - Stroke prevention and rhythm control therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources